We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
IS Pharma | LSE:ISPH | London | Ordinary Share | GB00B2QBY649 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 87.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
23/11/2009 16:09 | Try this : The title is "Variquel (Haemopressin) Update", dated today, if the link doesn't work | gogoneko | |
23/11/2009 14:53 | gogoneko, Can't find any update today. Nothing on their web site. can you give me more info? Thanks | clogue | |
23/11/2009 07:18 | Nice update to add substance to the news announced on June 22nd, although when I read the RNS title the first thing that came to mind was an FDA approval which I'd expected about now. | gogoneko | |
22/10/2009 12:29 | sell !!!!!!!!! before their bonus is announced .... | redrenault2 | |
21/10/2009 03:32 | getting close to 3 year highs. We should get news from the US soon and given the launch in europe already underway - I expect a period of very strong organic growth. The share price in my opinion has a long long way higher to go to reflect this. My impression is that the company is still viewed as the "old maelor", this will change as results are published. | asp5 | |
20/10/2009 13:42 | terrible, i sold out friday....oh well | targatarga | |
15/10/2009 12:42 | limited rise from here .. time to cut and run ... imho ... | redrenault2 | |
15/10/2009 12:10 | Yes, There have been a small number of buys in the region of 100,000 in the last 10 days. someone has confidence | connello | |
15/10/2009 11:55 | ON THE MOVE AGAIN! | philo124 | |
13/8/2009 11:59 | It should not be forgotton that the CEO has a good track record. He took elan europe from nothing to a 100M turnover business. He is very ambitious & the fact that the previous CFO was removed after only a brief stint shows he is not willing to hang around. The product pipeline is strong & will allow for turnover in a couple of years to be a multiple of what it is presently (based on my calcs). Just look at what has happened over the last 3 years. Also, I believe a number of scenarios are not fully factored into the price at the moment e.g. the fact that haemporessin will not have any competition for 7 years after lunch in the US & will be the only product in its niche available. There are other points as well which should allow the share price to push on considerably from these levels as results are published. The balance sheet is strong & the company will be in a good position to purchase products or competitors who are not in a strong position. The future is looking very rosy - especially because the business is well shielded from the credit crises & its consequences. Also the business model is low risk. | asp5 | |
13/8/2009 09:00 | It'll be interesting to see if there's a repeat of the heavy selling which kept a frustrating lid on things whenever it breached £1 back in 2007. [edit : the equiv of £1 back then anyway (15p I think) ] | gogoneko | |
03/8/2009 15:31 | Has definitely had the Midas touch today- excellent. | geraldus | |
03/8/2009 13:07 | Nice move up, some buying at 88p. Still cheap on 12 month view. | philo124 | |
03/8/2009 07:02 | Yes,says it's the next Shire....heady stuff indeed! | steeplejack | |
02/8/2009 19:38 | Gets a positive buy/hold and update from Midas in The Mail On Sunday. | geraldus | |
24/7/2009 13:57 | I'd be cautious about a desire to reduce the nominal value because such a tactic is frequently used to enable a company to issue new shares (for one reason or another) at a price lower than an existing nominal value. Maybe they're anticipating issuing a load of new shares at 50p for example. Given their past record of shoveling out millions of new shares on the cheap to mates to fund acquisitions it could be history about to repeat itself, or perhaps they may be thinking about issuing new shares in lieu of deferred considerations. | gogoneko | |
24/7/2009 13:44 | Daytraders, Thanks for the approach Chris - I still don't fully understand why but let's wait and see. | tackems | |
23/7/2009 16:04 | tackems i decided to email them a simialr question, and just got the reply, there not reversing really it seems, its all to do with the nominal value of the sp, below is my email to there Chief Financial Officer. Hi, i have a investment in your company of about £1958 2418 shares at todays price 81p mid, so my question is, if on tuesday at agm Resolution 8 splitting the shares is passed will that mean the share price will change and quantity of my shares change and be worth less than £1958 if mid is still same at 81p as today before the wednesday opening ? thankyou chris REPLY........ Dear Chris Assuming all the resolutions are passed, then there will be no change to either the number of shares you hold nor the share price. The resolution is designed simply to reduce the nominal value of the listed shares from 70p to 10p. The additional deferred shares that will be created will carry no voting rights, no rights to any dividends, and will not be listed on the stock market. They will almost certainly be re-purchased for 1p in due course. I hope this clarifies the situation for you. Kind regards Matthew Hall Chief Financial Officer | daytraders | |
23/7/2009 12:05 | maybe you could email your question to someone here , and let us know your reply, cheers | daytraders | |
22/7/2009 19:44 | Anybody understand why they are splitting the shares as part of Resolution 8 at the AGM? It seems strange that they have consolidated them already 7 for 1 and now they seem to be reversing this. Can anybody explain why in simple terms? tackems | tackems | |
08/7/2009 11:42 | Again!? It's last month's recommendation you're linking to, and as usual Growth Company had carefully forgetten to publish all relevant investment information. | gogoneko |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions